

JOSLIN DIABETES CENTER & JOSLIN CLINIC
CLINICAL GUIDELINE FOR ADULTS WITH DIABETES
5/21/2010

The Joslin Clinical Guideline for Adults with Diabetes is designed to assist primary care physicians and specialists individualize the care of, and set goals for adult, non-pregnant patients with diabetes. This Guideline focuses on the unique needs of the patient with diabetes. It is not intended to replace sound medical judgment or clinical decision-making and may need to be adapted for certain patient care situations where more or less stringent interventions are necessary. The objectives of the Joslin Clinical Diabetes Guidelines are to support clinical practice and to influence clinical behaviors in order to improve clinical outcomes and assure that patient expectations are reasonable and informed. Guidelines are developed and approved through the Clinical Oversight Committee that reports to the Medical Director of Joslin Diabetes Center. The Clinical Guidelines are established after careful review of current evidence, medical literature and sound clinical practice. This Guideline will be reviewed periodically and modified as clinical practice evolves and medical evidence suggests.

Joslin's Guidelines are evidence-based. In order to allow the user to evaluate the quality of the evidence used to support each standard of care, a modification of the GRADE system has been adopted. The table provided on page 13 describes the categories in which methodological quality and strength of recommendations have been classified.¹ Evidence levels are graded 1A through 2C, as indicated in brackets. Where evidence is not graded, recommendations are made based on the expertise of the Clinical Oversight Committee

APPROACH TO CARE

Team care: Diabetes is best managed by a team including medical specialists and diabetes educators. The patient needs to be informed of the roles of the various team members. If access to a team is not possible within the office practice, identify community resources. Clear communication between all providers is critical to ensure patients' needs are being met.

Patient centric: Diabetes is a condition that requires self-management. A collaborative counseling model (where the patient is involved in decisions and goal setting) helps promote behavior change. Whenever appropriate, with the patient's consent, involve family members and caregivers in medical visits and education.

Individualized treatment plan: Develop a treatment plan based on a thorough assessment which includes an understanding of not only the patient's medical needs, but all the factors that may affect the development of a treatment plan, including social history, race, cultural issues, ethnicity, education needs (including literacy and numeracy), and barriers to care. The plan identifies medical treatment, educational interventions and follow-up. Consider use of a flow sheet to track care parameters and identify areas for intervention.

Regular medical visits: The frequency of visits for ongoing care should be individualized, but usually includes at least 2-4 routine visits/year. Special attention should be given to patients who fail to keep scheduled appointments, have frequent hospitalizations or missed days of work/school. Since many factors contribute to patients' ability to manage their care, the provider should:

- engage patients in identifying and resolving contributing factors or barriers to under-utilization or over-utilization of healthcare services
- consider referral to a diabetes educator (DE), social services or a mental health professional to address possible barriers and/or psychosocial problems
- establish a process of follow-up communication regarding achievement (progress) of the treatment plan, sustaining behaviors and identifying obstacles to care

A1C

Diagnosis:

An A1C* level of 6.5% or higher on 2 separate days is acceptable for diagnosis of diabetes. [1B]. However, some individuals may have an A1C < 6.5% with diabetes diagnosed by previously established blood glucose criteria. Those with an A1C of 5.7-6.4% are at increased risk for diabetes, and should be treated with lifestyle changes and followed more frequently.

* *The A1C should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program (NGSP) certified and standardized to the Diabetes Control and Complications Trial (DCCT) assay.*

Follow-up visits:

Check the hemoglobin A1C (A1C) 2-4 times a year as part of the scheduled medical visit, with frequency dependent upon revision of the treatment program and the need to reinforce behavior changes. Increase frequency when therapy has changed and/or when glycemic goals are not met. Having the A1C result at the time of the visit can be useful in making timely treatment decisions. [1C]

Goal:

A1C target goal should be individualized for each patient. A goal of < 7% is chosen as a practical level for most patients to avoid the risk of complications. Achieving normal blood glucose is recommended if it can be done practically and safely. [1B]

The goal may be modified based upon presence or absence of microvascular and/or cardiovascular complications, cognitive status and life expectancy. [1A]

Some clinicians may translate patients' A1C level into their estimated average glucose level (eAG), based upon the work of the A1C Derived Average Glucose Study (ADAG). This is also a valid metric to use in following diabetes treatments.

Joslin's A1C goal is consistent with that of the ADA. Other expert panels, such as AACE/IDF suggest that the goal of treatment should be $\leq 6.5\%$.

For patients with longstanding type 2 diabetes with pre-existing CVD, or high CAD risk (diabetes plus 2 or more additional risk factors), consider revising A1C goals to maintain safety. [1B]

Treatment:

If A1C is $\geq 7\%$ and $< 8\%$, or above the individualized goal for 6 or more months:

- Review and clarify the management plan with the patient with attention to:
 - nutrition and meal planning [1B]
 - physical activity [1A]
 - medication administration schedule, technique and practices [1A]
 - self-monitoring blood glucose (SMBG) schedule and technique [1A]
 - treatment of hypoglycemia and hyperglycemia
 - sick day management practices
- Reassess goals and adjust medication as needed. [1A]
- Establish and reinforce individualized glycemic goals with patient.
- Consider referring patient to diabetes educator (DE) for evaluation, diabetes self-management education (DSME) and ongoing consultation. [2A]
- Consider referral to registered dietitian (RD) for medical nutrition therapy (MNT). [2B]
- Schedule follow-up appointment within 3-4 months or more frequently as situation dictates.

If A1C is $\geq 8\%$

- Review and clarify the plan as previously noted. [1B]
- Assess for psychosocial stress. [1C]
- Establish and reinforce individualized glycemic goals with the patient.
- Intensify therapy.

- Refer patient to DE for evaluation, DSME and ongoing consultation. Document reason if no referral initiated. [1A]
- Refer patient to RD for MNT. [1B]

If history of severe hypoglycemia or hypoglycemia unawareness (a condition in which the patient is unable to recognize symptoms of hypoglycemia until they become severe):

- assess for changes in daily routine such as decreased food intake or increased activity [1C]
- refer to DE for evaluation, DSME and hypoglycemia prevention; encourage family/friend attendance
- review use of glucagon
- consider revising A1C goal [2C]
- discuss and reinforce goals with patient
- adjust medications accordingly
- if insulin-treated, consider use of a more physiologic insulin replacement program [1C]
- consider and screen for other medical causes [1C]
- consider referral for blood glucose awareness training, if available [1B]
- consider use of continuous glucose monitoring (CGM)
- schedule follow-up appointment within 1-2 months. If history of recent, severe hypoglycemia or change in pattern of hypoglycemia, recommend increase in frequency of communicating blood glucose levels to provider or diabetes educator. [1B]

GLUCOSE MONITORING

Self-monitoring of blood glucose (SMBG) is an important component of the treatment program for all people with diabetes. Its use is to gauge treatment efficacy, help in treatment design, provide feedback on the impact of nutritional intake and activity, provide patterns that assist in medication selection, and for those on insulin, assist in daily dose adjustments. [1A]

Goals for glycemic control for people with diabetes are:

- Fasting glucose: 70-130 mg/dl
- 2-hour postprandial glucose: < 180 mg/dl
- Bedtime glucose: 90-150 mg/dl

The frequency of SMBG is highly individualized and should be based on such factors as glucose goals, medication changes and patient motivation. Most patients with type 1 diabetes should monitor 4-6 times per day. Some patients may need to monitor even more frequently. For patients with type 2 diabetes, the frequency of monitoring is dependent upon such factors as mode of treatment and level of glycemic control. [1C]

To obtain meaningful data for treatment decisions, it is helpful for the patient to monitor for several consecutive days (e.g., 2-4 days). In addition to obtaining fasting and preprandial glucose levels, consider obtaining glucose readings 2-3 hours postprandially, as postprandial

hyperglycemia has been implicated as an additional cardiovascular risk factor. [1C]

Postprandial monitoring is particularly recommended for patients who:

- have an elevated A1C but fasting glucose is at target
- are initiating intensive (physiologic) insulin treatment programs
- are experiencing problems with glycemic control
- are using glucose-lowering agents targeted at postprandial glucose levels
- are making meal planning or activity adjustments

1-hour postprandial glucose monitoring should be considered:

- during pregnancy
- for those patients using alpha-glucosidase inhibitors

Encourage the patient to bring SMBG results (written records or meter for downloading) to each visit for review with provider/educator.

Alternate Site Monitoring:

Blood glucose levels from sites such as the upper arm, forearm, and thigh may lag behind samples taken from the fingertips particularly when glucose levels are changing rapidly. Glucose levels may change rapidly with exercise, eating, after insulin administration or with hypoglycemia. For this reason, alternate site testing is not recommended in the following situations:

- when the blood glucose may be changing rapidly
- for patients using intensive insulin treatment programs
- if hypoglycemia is suspected
- in patients with hypoglycemia unawareness

HYPOGLYCEMIA

Prompt action is recommended for the treatment of hypoglycemia. When possible, the patient should confirm symptoms with SMBG to document hypoglycemia. All patients with type 1 diabetes should ensure that a family member/companion/caregiver knows how to administer a glucagon injection in the event the patient is unable or unwilling to take carbohydrate orally. [1C]

Treatment:

- Treat as mild-moderate hypoglycemia if patient is symptomatic or unable to confirm hypoglycemia with SMBG, or if blood glucose levels are >50 mg/dl and <70 mg/dl (<90 mg/dl at bedtime or overnight).
- Caution patient to avoid alternate site monitoring with blood glucose meter when hypoglycemic.
- For mild to moderate hypoglycemia (plasma glucose 51-70 mg/dl most times of the day and <90 mg/dl bedtime or overnight), begin with 15-20 grams carbohydrate (1/2 cup juice or regular soft drink, 3-4 glucose tabs, or 8-10 hard candies). [1C]

- If glucose level is ≤ 50 mg/dl, consume 20-30 grams carbohydrate. [1C]
- Recheck blood glucose after 15 minutes. [1B]
- Repeat hypoglycemia treatment if blood glucose does not return to normal range after 15 minutes. [1C]
- Follow with additional carbohydrate or snack if next meal is more than one hour away. [1C]
- If hypoglycemia persists after second treatment, patient or companion should be instructed to contact healthcare provider.
- In event of severe hypoglycemia (altered consciousness, unable to take carbohydrate orally, or requiring the assistance of another person) treat with glucagon and/or intravenous glucose. [1C]
- For patients with hypoglycemia unawareness, the threshold for treatment of hypoglycemia needs to be individualized. [2C]
- For patients using real-time CGM, check 15 minutes post treatment using a finger stick and not the sensor reading. Due to the physiologic lag between blood and interstitial glucose, the sensor will yield a lower result and can lead to over-treatment.

Education:

- Instruct patient to obtain and wear or carry diabetes identification.
- Inform patient of need to check blood glucose before driving, periodically during a long drive, and when operating heavy machinery. [1B]
- Instruct patient to carry treatment for hypoglycemia at all times.
- Identify possible causes of hypoglycemia in order to prevent it. [1C]
- Be clear in communicating modified treatment goals in individuals with hypoglycemia unawareness (see section in guideline on *Hypoglycemia Unawareness*). [1C]

DIABETES SELF-MANAGEMENT EDUCATION (DSME) and MEDICAL NUTRITION THERAPY (MNT)

Individuals with newly diagnosed diabetes should receive:

- DSME according to National Standards for Diabetes Self-Management Education [1A]
- individualized Medical Nutrition Therapy (MNT) [1A]
- multiple visits with diabetes educator (DE) to evaluate progress towards goals [1A]

Individuals with existing diabetes should receive:

- an annual assessment of the need for DSME and MNT, and referral, as appropriate, to a trained DE [2B]
- initial and ongoing assessment of psychosocial issues [1C]

PHYSICAL ACTIVITY

Guidelines for healthy adults:

- Physical activity should be an integral component of the diabetes care plan to optimize glucose control, decrease cardiovascular risk factors, and achieve or maintain optimal body weight. [1B]
- A moderate-intensity aerobic (endurance) physical activity minimum of 30 minutes (min) 5 days per week or vigorous-intensity aerobic physical activity for a minimum of 20 min 3 days per week should be achieved unless contraindicated. Activity can be accumulated toward the 30-min minimum by performing bouts each lasting 10 or more minutes.
- A target of 60-90 minutes, 6-7 days per week is encouraged for weight loss if overweight or obese. [1B]
- To increase lean body mass, resistance training should be incorporated into the activity plan 3-4 days per week, and include upper, core and lower body strengthening exercises using free weights, resistance machines or resistance bands.
- Stretching exercises should be done when muscles are warm or at the end of the activity plan to loosen muscles and prevent soreness. [1B]

Guidelines for adults with medical or physical limitations:

- A moderate-intensity aerobic (endurance) physical activity minimum of 30 min 5 days per week or vigorous-intensity aerobic physical activity for a minimum of 20 min 3 days per week should be achieved, as feasible, unless contraindicated. Activity can be accumulated toward the 30-min minimum by performing bouts each lasting 10 or more minutes.
- To increase lean body mass, resistance training should be incorporated into the activity plan 3-4 days per week, as feasible, and include upper, core and lower body strengthening exercises using free weights, resistance machines or resistance bands.
- Incorporate balance exercises to prevent falling and injury.
- All adults should consult their healthcare provider and/or see an exercise physiologist to discuss a safe exercise program that is appropriate to their abilities.

CARDIOVASCULAR HEALTH

(Also see sections on *Lipids, Blood Pressure, Physical Activity and Smoking*)

Treatment:

A daily enteric-coated ASA (75-162 mg) unless contraindicated * as a primary prevention strategy for men ≥ 50 years of age [2B] and for women ≥ 60 years of age [2B] with ONE or more of the following risk factors:

- Family history of premature** CAD or stroke
- HTN
- Current cigarette smoker
- Micro/macro albuminuria

- Hyperlipidemia

Recommend a daily enteric-coated ASA (75-162 mg) or clopidogrel (75 mg, if aspirin intolerant) or another agent of the class, as a secondary prevention strategy for anyone with ONE or more of the following: [1A]

- History of MI, angina, or documented CAD
- Vascular revascularization
- Non-hemorrhagic stroke
- TIA
- PAD

**Possible contraindications for antiplatelet therapy may include allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal bleeding and clinically active hepatic disease. Eye disease is usually not a contraindication for ASA therapy.*

***Premature – 1st degree male relatives younger than 55; 1st degree female relatives younger than 65*

Consider using beta-blocker in all patients with a history of MI or with documented CAD unless contraindicated. [1A]

Consider recommending aerobic exercise if not clinically contraindicated and a weight-loss program if patient is overweight or obese. [1A]

Consider using ACE inhibitors (or ARBs if ACE inhibitors not tolerated) in patients with known CAD or cardiovascular risk factors and age 55 or greater. [1A]

Thiazolidinediones (pioglitazone, rosiglitazone) are contraindicated in patients with NYHA classes III and IV and conditions of fluid overload (i.e., CHF).

Meta-analyses of clinical studies showed rosiglitazone to be associated with an increased risk of myocardial ischemic events such as angina or myocardial infarction. Other studies comparing rosiglitazone to some other approved oral antidiabetic agents or placebo have not confirmed or excluded this risk. In the only long-term, randomized clinical trial (RECORD), there was no significant increase in the risk of cardiovascular events with rosiglitazone.

Indications for conducting a stress test:

Based on current research and understanding of coronary artery disease in diabetes, it is reasonable to screen patients with diabetes who: [1C]

- complain of typical or atypical chest pain
- have an abnormal ECG
- have a diagnosis of peripheral artery disease (PAD) or carotid disease
- are >35 years of age with sedentary lifestyle about to start a rigorous exercise program.

There is currently no strong evidence to support screening asymptomatic patients with type 2 diabetes for silent myocardial ischemia. [2B]

Patients with autonomic neuropathy may have increased risk of asymptomatic ischemia and therefore warrant careful attention. [1B]

If stress testing is performed, either rMPI or echocardiography with ECG monitoring is recommended. Exercise stress is preferred, if resting ECG is normal and patient is able to exercise, as the response to exercise is an important prognostic factor. If the patient cannot adequately exercise, pharmacologic stress testing is warranted.

LIPIDS

Screen:

Adults should be screened annually for lipid disorders with measurements of serum cholesterol, triglycerides, and LDL and HDL cholesterol, preferably fasting. [1C]

Lipid Goals: (mg/dl)

LDL-Cholesterol (LDL-C):

- <100 if no diagnosed CVD [1A];
- <70 if diagnosed CVD [1B]

HDL-Cholesterol (HDL-C):

- >40 (men); >50 (women) [2C]

Triglycerides: <150 (fasting) [2C]

Treatment:

All patients should receive information about a meal plan designed to lower blood glucose and improve lipids, physical activity recommendations, and risk reduction strategies. Consultation with appropriate education discipline is preferred. [1A]

Institute therapy after abnormal values are confirmed.

For patients in whom CVD is not yet diagnosed:

If LDL-C \geq 100 mg/dl:

- optimize glycemic control [1A]
- refer to RD for intensive dietary modification and therapeutic lifestyle changes (TLC) [1A]
- consider referral to exercise specialist or DE for exercise prescription
- recheck lipids within 6 weeks
- if LDL-C remains >100, if age 40 yrs of age and above [1A], or if age <40 yrs of age and multiple risk-factors [2C], initiate medication with goal of lowering LDL-C to <100, preferably with a statin, or by ~30-40% if goal not achieved by maximally tolerated statin therapy

If LDL-C <100 mg/dl:

Consider statin therapy if age >40 yrs and one more CVD risk factor is present (hypertension, smoking, albuminuria or family history of premature CVD). [1A]

Patients with cardiovascular disease (CVD):

If LDL-C \geq 70 mg/dl:

- optimize glycemic control [1A]

- refer to RD for intensive dietary modification and therapeutic lifestyle changes (TLC) [1A]
- consider referral to exercise specialist or DE for exercise prescription [1A]
- consider starting lipid lowering agent (preferably statin) immediately if LDL-C is >100 [1A]
- recheck lipids within 6 weeks
- if LDL-C remains >70, initiate/titrate medication (preferably a statin) with goal of lowering LDL-C to <70, or by ~30-40% if goal not achieved by maximally tolerated statin therapy [1A]. May require combination of a statin with another lipid lowering agent to achieve this goal. [1B]

Consider bile acid sequestrant or cholesterol absorption inhibitors or niacin (alone, or in combination therapy) for patients with statin intolerance or unacceptable adverse event.

Patients with LDL-C at goal and fasting triglycerides \geq 150 mg/dl or HDL-C \leq 40 mg/dl:

- optimize glycemic control [1A]
- refer to RD for dietary modification and therapeutic lifestyle changes (TLC) [1A]
- consider referral to exercise specialist for exercise prescription
- recheck lipids within 6 weeks
- in patients with fasting triglyceride levels 200-499 mg/dl, calculate non-HDL-C (total cholesterol minus HDL-C) and consider starting or titrating statin if non-HDL-C >130 [1C]
- consider adding fibrate or niacin if fasting triglycerides >200 and/or HDL-C \leq 40 mg/dl after non-HDL-C goal is met [2C]
- if triglycerides >500 mg/dl, initiate treatment with very low fat diet and fibrate for prophylaxis against acute pancreatitis; rule-out other secondary causes; reassess lipid status when triglycerides <500 mg/dl [1A]
- if fasting triglycerides remain >500 mg/dl after initiation of fibrate and /or niacin, consider the addition of fish oil (to provide 2-4 g omega-3 fatty acids daily)

BLOOD PRESSURE

Screen:

- Check BP at all routine visits after patient has sat for 5 minutes. Use proper-sized cuff and arm position. Postural BP should be checked initially, and as clinically indicated, and if orthostatic (defined as a fall in SBP of 20-30 mmHg or DBP of 10-15 mmHg or greater upon change in position) check at each follow-up visit. [1C]
- Consider initiating pharmacologic therapy if initial blood pressure is 140/90 and is confirmed by a subsequent measurement.

Goal:

- BP goal for each patient >18 years of age is <130/80 mmHg and modified for comorbidities. [1B]
- BP goal for patients with proteinuria >1 g is <125/75 mmHg. [1C]
- Initial goal for patients with isolated systolic HTN (SBP >180 mmHg and DBP <80 mmHg) is a SBP <160 mmHg.
- Initial goal for patients with SBP 160-179 mmHg is to lower SBP by 20 mmHg. If well tolerated, lower BP goals may be indicated. [1B]
- No clear evidence exists for significant benefits to be gained by lowering SBP to <140 mmHg in those with CHD or multiple risk factors. [1B]

Treatment:

If SBP 130-139 mmHg or DBP 80-89 mmHg, a 3-month trial of lifestyle modification is warranted as follows: [1C]

- counsel about meal plan, activity, weight loss, sodium reduction, alcohol and stress reduction
- consider referral to RD for medical nutrition therapy (MNT)
- encourage home BP monitoring
- instruct patient to have BP checked on 3 separate occasions before next appointment
- follow-up with healthcare provider within 2-4 weeks
- initiate or adjust therapy with antihypertensive agents as clinically indicated if BP remains above goals

Studies have shown that aggressive management and control of blood pressure may result in long-term benefits

If BP remains >130/80 mmHg after 3 months of attempted lifestyle modification, or if BP >140/90 mmHg at initial visit, add a pharmacological agent to lifestyle modification.

Drug therapy:

Efficaciousness is the most important consideration in choosing an initial anti-hypertensive drug. In that sense, any available antihypertensive drug can be an appropriate choice; however, other considerations (presence of proteinuria, co-existing CAD, or cost) dictate a preference for ACE inhibitors, ARBs, beta-blockers and diuretics. [1A]

ACE inhibitors or ARBs are the drugs of choice, after achieving A1C and blood pressure goals, for patients with urine albumin >30 mcg/mg. These drugs require monitoring of serum creatinine and K⁺ within 1-2 weeks of starting therapy and periodically thereafter. [1A] (See section on *Renal Disease and Micro-Macro Albuminuria*)

SMOKING**Screen:**

- Assess patient's smoking status on a routine basis.

Treatment: (*If patient smokes*)

- Discuss rationale for and strongly recommend smoking cessation. [1A]
- Review options available to assist in smoking cessation, including medications and cessation programs. [1B]

RENAL DISEASE AND MICRO-MACRO ALBUMINURIA**Screen:**

Measure serum creatinine at least annually to estimate glomerular filtration rate (GFR) regardless of degree of urine albumin excretion. (See Joslin's *Guideline for Specialty Consultation/Referral* for guidance as to when to refer to a renal specialist.) [1C]

Estimate GFR (eGFR) using the MDRD equation. If eGFR is <60 ml/min, evaluate for complications of kidney disease (anemia, hyperparathyroidism, and vitamin D deficiency).

Screen for micro/macro albuminuria by checking urine albumin/creatinine (A/C) ratio as follows:

- type 1 patients within 5 years after diagnosis and then yearly [1C]
- type 2 patients at diagnosis (after glucose has been stabilized) and then yearly [1C]
- annually in all patients up to age 70 years [2C]
- as clinically indicated in patients >70 years of age

Micro/macro albuminuria is recognized as a major independent risk factor for CAD in patients with diabetes. Albuminuria may be measured with a spot or timed urine collection. Spot urine is preferred for simplicity.

Continue use of routine urinalysis as clinically indicated. [2C]

Consider referral to nephrologist to:

- assess cause(s) of impaired kidney function including assessing for non-diabetes kidney disease
- maximize therapies aimed at slowing progression of kidney disease (e.g., blood pressure control and reduction of urine protein level)
- treat complications of kidney disease

Treatment:

If A/C ratio <30 mcg/mg or timed urine albumin <30 mg/24 hr:

- recheck in 1 year

If A/C ratio 30-300 mcg/mg or timed urine albumin 30-300 mg/24 hr:

- confirm presence of microalbuminuria with at least 2 of 3 positive collections done within 3-6 months. In the process, rule out confounding factors that cause a false-positive such as UTI, pregnancy, excessive exercise, menses or severe hypoglycemic event. [1C]
- consider testing first morning urine

- consider consult with nephrologist for blood pressure control, successive increases in microalbumin and other issues (i.e., GFR <60 ml/min) [2C]

Once confirmed:

- evaluate BP and initiate/modify aggressive blood pressure treatment to achieve a BP of <130/80 mmHg [1A]
- recommend patient self-monitor BP with portable cuff and maintain a record/log. The monitoring schedule should be determined with the healthcare provider and is based on patient circumstance.
- strive to improve glycemic control with an optimal goal A1C of <7% or as otherwise clinically indicated [1A]
- refer to diabetes educator for glucose management
- initiate/ modify ACE inhibitor or ARB treatment if microalbuminuria persists. Check K⁺ and creatinine 1-2 weeks after making changes. [1A]
- repeat A/C ratio at least every 6 months. Consider increase in frequency when changes in medication are made. [2C]

If A/C ratio > 300 mcg/mg (> 300 mg/24 hr) or proteinuria (positive dipstick for protein or ≥ 30 mg/dl):

- follow all guidelines as stated for A/C ratio 30-300 mcg/mg
- consider BP goal of < 125/75 mmHg [2B]
- consult with nephrologist if: [1C]
 - rapid rise in serum creatinine, abnormal sediment, or sudden increase in proteinuria
 - need to refine treatment program to prevent further deterioration
 - problems with ACE inhibitors, difficulties in management of high BP, or hyperkalemia
 - etiology of nephropathy is questionable
 - management of hyperphosphatemia presents difficulties
 - anemia due to renal disease
- consider reducing protein in the diet [1B]
- consider nutrition referral

EYES

Exam Schedule:

Refer patient for comprehensive dilated eye exam or validated retinal imaging to determine level of retinopathy.

- Type 1: initial eye exam within 3 years after diagnosis of diabetes once patient is 9 years of age or older and annually thereafter. [1B]
- Type 2: at diagnosis and annually thereafter [1B]
- Pregnancy in pre-existing diabetes: prior to conception and during first trimester with follow-up as determined by first trimester exam and 6-12 weeks post partum. [1B]

For physiologic insulin therapy (pump therapy or multiple daily injections): consult with patient’s eye doctor or evaluate retinal status with validated retinal imaging to

determine level of retinopathy and appropriate follow-up care prior to initiating physiologic insulin therapy.

Treatment:

Aggressively treat known medical risk factors for retinopathy: [1A]

- Strive to improve glycemic control with optimal A1C goal of <7%.
- Monitor eye disease carefully when intensifying glycemic control.
- Strive for BP <130/80 mmHg.
- Treat micro/macro albuminuria.
- Strive to maintain total cholesterol, LDL, HDL and triglyceride levels as per the recommendations outlined in the *Lipids* Section of this Guideline.
- Treat anemia.

Revise activity program depending on the level of retinopathy.

Reinforce follow-up with eye care provider for any level of retinopathy including no apparent retinopathy. The frequency of follow-up is dependent upon the level of retinopathy and is determined by the eye care provider.

- For high-risk proliferative diabetic retinopathy, scatter (panretinal) photocoagulation is indicated promptly. [1A]
- For clinically significant macular edema (CSME), focal laser and/or intravitreal ranibizumab injection is generally indicated regardless of level of retinopathy. [1A]
- The level of diabetic retinopathy and diabetic macular edema (DME) generally determines follow-up.* [1A]

If No Diabetic Retinopathy:

12 months

If Mild Nonproliferative Diabetic Retinopathy:

Without DME 12 months
With DME** 3-4 months

If Moderate Nonproliferative Diabetic Retinopathy:

Without DME 6-9 months
With DME** 3-4 months

If Severe - Very Severe Nonproliferative Diabetic Retinopathy:

Without DME*** 3-4 months
With DME** 3-4 months

If Proliferative Diabetic Retinopathy less than High-Risk:

Without DME** * 1 week – 3-4 months
With DME** 1 week – 3-4 months

If High-Risk Proliferative Diabetic Retinopathy

With or without DME – scatter laser surgery with follow-up in 3 months

*The presence of known risk factors for onset and progression of retinopathy may suggest follow-up at shorter intervals for all levels of retinopathy

** Focal laser surgery and/or intravitreal ranibizumab injection is generally indicated for CSME. If receiving intravitreal ranibizumab injection, follow-up may be as frequent as monthly

*** Scatter laser surgery may be indicated, especially for type 2 diabetes or type 1 diabetes of long duration

Intravitreal injections of steroids and anti-VEGF agents other than ranibizumab, are sometimes used in clinical practice to treat macular edema despite limited studies on their effectiveness or safety to date. These modalities are currently under rigorous investigation to further define their role.

PERIPHERAL NEUROPATHY

Screen:

- Ask patient about loss of sensation in the limbs, symptoms of pain, tingling, paresthesia, weakness or gait instability.
- Evaluate feet for sensation and reflexes.
- Laboratory screening with complete blood count, lipid panel, thyroid panel, B12 level (with methylmalonic acid +/- homocysteine), serum and urine protein electrophoresis, as clinically indicated.
- Neurophysiologic testing (EMG, quantitative sensory testing) should be considered in atypical cases.
- Assess for symptoms of autonomic neuropathy such as erectile dysfunction, gastroparesis, or postural hypotension.

Frequency:

- For patients with type 1 and 2 diabetes without complications, conduct symptom and examination screen at time of diagnosis and at least annually. [1C]
- For the “at-risk patients,”* conduct symptom and examination screen at all routine interval visits. [1C]
- Laboratory screening at the time of diagnosis of diabetes or with change in symptoms or examination. [1C]
- Screening for cardiovascular autonomic neuropathy at the time of diagnosis of type 2 diabetes, or 5 years after diagnosis of type 1 diabetes. Screening should be repeated yearly or with development of symptoms. [1C]
- Neurophysiologic testing only for atypical cases. [1C]

*“*At-Risk Patients*” include patients who smoke, have vascular insufficiency, neuropathy, retinopathy, nephropathy, history of ulcers or amputations, structural deformities, infections, skin/nail abnormality, are on anticoagulation therapy or who cannot see, feel or reach their feet.

Treatment:

For patients with acute problems or who are “at risk”:

- Consider referral to neurologist for:
 - atypical neuropathy
 - rapidly progressive symptoms
 - severe pain unresponsive to first line therapy
 - weakness suggestive of diabetic amyotrophy

For patients with symptoms related to diabetic peripheral or autonomic neuropathy:

- consider medications as they improve quality of life [1A]

FEET

Screen:

Screening should include:

- questions about loss of sensation in the limbs, or symptoms of pain, tingling or other paresthesia
- foot evaluation for sensorimotor (monofilament), skin and soft tissues integrity, nail condition, vascular sufficiency (pedal pulses) and biomechanical integrity
- examination of shoes for wear

Frequency:

- For patients with type 1 and 2 diabetes without complications, conduct foot screen at time of diagnosis and at least annually thereafter. [1C]
- For the “at-risk patients,”* check feet at all routine interval visits. [1C]

*“*At-Risk Patients*” include patients who smoke, have vascular insufficiency, neuropathy, retinopathy, nephropathy, history of ulcers or amputations, structural deformities, infections, skin/nail abnormality, are on anticoagulation therapy or who cannot see, feel or reach their feet.

Treatment:

For patients with acute problems or who are “at risk”:

- refer to podiatrist for routine care and evaluation [1B]
- refer to DE for foot care training* [1C]
- consider referral to neurologist for:
 - atypical neuropathy
 - rapidly progressive symptoms
 - severe pain unresponsive to first line therapy
 - weakness suggestive of diabetic amyotrophy

*Foot care training:

Foot care training should address:

- avoidance of foot trauma
- daily foot inspection
- nail care
- proper footwear
- impact of loss of protective sensation on morbidity
- need for smoking cessation
- action to take when problems arise
- importance of glucose control on disease progression

For current ulcer or infection: mild [1C]**

**** Mild Infection or Ulcer**

Superficial (no foul odor) No significant ischemia
No bone or joint involvement No systemic toxicity
Minimal or no cellulitis (< 2 cm)

- instruct patient in non-weight bearing, if appropriate
- apply local dressings
- consider baseline x-ray to evaluate for bone integrity and possible osteomyelitis
- consider systemic antibiotic therapy
- refer to podiatrist for debridement or further treatment
- refer for foot care training
- ensure follow-up appointments are kept

For limb-threatening* ulcer or infection: [1C]**

***** Limb-threatening:**

Deep ulcer Bone or joint involvement
Gangrene Lymphangitis
>2 cm cellulitis Systemic toxicity
Significant ischemia No social support system
Immunocompromised Foul odor in ulcer
Osteomyelitis, presumed to be present if probed to the bone.

- consider hospitalization
- refer to a podiatrist and vascular surgeon for immediate evaluation and treatment

MENTAL HEALTH

A psychosocial evaluation should be an integrated component of the initial assessment and the ongoing care of all patients with diabetes and should be strongly considered in the following situations:

Newly diagnosed diabetes:

Assess at least the following:

- ability to cope with the emotional impact and lifestyle changes of diabetes
- level of social support
- type and degree of non-diabetes related stress

Newly diagnosed complications from diabetes:

Assess at least the following:

- ability to cope with the emotional impact and lifestyle changes
- level of social support
- type and quantity of non-diabetes related stress

When changes in treatment, self-care, or metabolic stability as evidenced by:

- diabetes burnout or lack of adherence with treatment regimen: consider using PAID as a screening tool.
- symptoms of depression: consider using PHQ-9 or PHQ-2 as a screening tool
- symptoms of anxiety (e.g., compulsive SMBG)

- A1C >10% and inquiry indicates insulin mismanagement by the patient (omission or under-dosing)
- exaggerated fear of hypoglycemia
- recurrent DKA
- family conflict related to diabetes
- substance abuse: consider use of CAGE alcohol screening tool

IMMUNIZATIONS

Recommend the following vaccines:

- influenza vaccine: yearly for all adult patients with diabetes [1B]
- pneumococcal vaccine: once for all patients with diabetes. [1B]
 - Patients ≥ 65 years of age should receive a second dose of pneumococcal vaccine if they received the previous dose ≥ 5 years earlier **and** they were < 65 years of age when they received the previous dose.
- consider vaccines for other disease prevention such as for herpes zoster

WOMEN'S HEALTH

(Refer to Joslin's *Guideline for Detection and Management of Diabetes in Pregnancy* for more details)

- Counsel women with the potential for conception about contraception use and relationship of blood glucose control to fetal development and pregnancy outcomes. [1C]
- At initial and annual visit, discuss sexual function.
 - Assess for infectious, hormonal, psychological, or structural etiologies if dysfunction exists.
 - Refer to specialist as indicated. [1C]
- Follow appropriate guidelines for pap/pelvic and mammography screening for primary care patients. [1A]
- Individualize approach to bone health for women with risk factors for osteoporosis, including surgical and natural menopause. [1B]
 - Ensure adequate intake of calcium and vitamin D.

MEN'S HEALTH

- At initial and annual visit, discuss sexual function.
- Assess for hormonal, psychological, or structural etiologies if dysfunction exists. [1C]
- For men with type 2 diabetes, consider screening for low testosterone:
 - screen with total testosterone, and sex hormone binding globulin
- Refer to specialist as indicated.

DENTAL CARE

- Periodontal disease is associated with suboptimal diabetes control and may be a risk factor for cardiovascular disease.
 - At initial visit and annually, discuss need for dental exams at least every six months.
- If evidence of gingivitis, may need dental evaluation/treatment every 3-4 months.
 - Refer to dental specialist for oral symptoms such as sore, swollen, or bleeding gums, loose teeth or persistent mouth ulcers. [1C]

List of Abbreviations

AACE - American Association of Clinical Endocrinologists

A1C - glycohemoglobin (hemoglobin A_{1c})

A/C Ratio - albumin/creatinine ratio

ACE inhibitor - angiotensin-converting enzyme inhibitor

ADA - American Diabetes Association

ADAG - A1c-Derived Average Glucose study

ARBs - angiotensin receptor blockers

ASA - aspirin

BP - blood pressure

CAD - coronary artery disease

CAGE - Alcohol screening questionnaire

CGM - Continuous glucose monitoring

CHF - Congestive heart failure

CSME - clinically significant macular edema

CVD - cardiovascular disease

CVD - cardiovascular disease, including coronary heart disease, peripheral vascular disease, and cerebrovascular disease

DBP - diastolic blood pressure

DCCT - Diabetes Control and Complication Trial

DE - diabetes educator

DKA - diabetic ketoacidosis

DME - diabetic macular edema

DSME - diabetes self-management education

eAG - estimated average blood glucose

ECG - electrocardiogram

eGFR - estimated glomerular filtration rate

EMG - electromyogram

GFR - glomerular filtration rate

GRADE - Grading of Recommendations, Assessment, Development and Evaluation

HDL-C - high-density lipoprotein cholesterol

HTN - hypertension

IDF - International Diabetes Federation

K+ - potassium

LDL-C - low-density lipoprotein cholesterol

MDRD - Modification of diet in renal disease study equation

http://nkdep.nih.gov/professionals/gfr_calculators/orig_con.htm

MI - myocardial infarction

Min - minutes

MNT - medical nutrition therapy

NGSP - National Glycohemoglobin Standardization Program

NYHA - New York Heart Association

PAD - peripheral artery disease

PAD - peripheral Arterial Disease

PAID - Problem Areas in Diabetes

PHQ-2 - Patient Health Questionnaire 2 questions

PHQ-9 - Patient Health Questionnaire, 9 questions

PVD - peripheral vascular disease

RD - registered dietitian

RECORD study - Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

rMPI - radionuclide myocardial perfusion imaging

SBP - systolic blood pressure

SMBG - self-monitoring of blood glucose

TIA - transient ischemic attack

TLC - therapeutic lifestyle changes

UTI - urinary tract infection

VEGF - vascular endothelial growth factor

Approved by the Joslin Clinical Oversight Committee on 05/20/2010

The Joslin Clinical Oversight Committee gratefully acknowledges: Elena Savoia, MD, MPH, Acting Director, Center for Public Health Preparedness, Harvard School of Public Health, Boston, in the supervision of the grading process and Peter Polewski, graduate student, for his assistance with the literature search and review.

Joslin Clinical Oversight Committee

Om Ganda, MD - Chairperson	Medha Munshi, MD
Richard Beaser, MD	Jo- Anne Rizzotto, MEd, RD, CDE
Elizabeth Blair, MS, ANP-BC, CDE	Kristi Silver, MD
Amy Campbell, MS, RD, CDE	Susan Sjostrom, JD
Cathy Carver, ANP-BC, CDE	Kenneth Snow, MD
Jerry Cavallerano, OD, PhD	Robert Stanton, MD
David Feinbloom, MD	William Sullivan, MD
Richard Jackson, MD	Howard Wolpert, MD
Lori Laffel, MD, MPH	John Zrebiec, LICSW
Melinda Maryniuk, MEd, RD, CDE	Martin J. Abrahamson, MD (<i>ex officio</i>)

Grading System Used in Guideline

Grade of Recommendation	Clarity of risk/benefit	Quality of supporting evidence
1A Strong recommendation High quality of evidence	Benefits clearly outweigh risk and vice versa.	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.
1B Strong recommendation Moderate quality of evidence	Benefits clearly outweigh risk and burdens, or vice versa.	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodological flaws, indirect or imprecise), or very strong evidence of some other research design. Further research is likely to have an impact on our confidence in the estimate of the benefit and risk and may change the estimate.
1C Strong recommendation Low quality of evidence	Benefits outweigh risk and burdens, or vice versa.	Evidence from observational studies, unsystematic clinical experience, or from randomized controlled trials with serious flaws. Any estimate of effect is uncertain.
2A Weak recommendation High quality of evidence	Benefits closely balanced with risks and burdens.	Consistent evidence from well performed randomized controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.
2B Weak recommendation Moderate quality of evidence	Benefits closely balanced with risks and burdens; some uncertainty in the estimates of benefits, risks and burdens.	Evidence from randomized controlled trials with important limitations (inconsistent results, methodological flaws, indirect or imprecise), or very strong evidence of some other research design. Further research is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.
2C Weak recommendation Low quality of evidence	Uncertainty in the estimates of benefits, risks and burdens; benefits may be closely balanced with risks and burdens.	Evidence from observational studies, unsystematic clinical experience, or from randomized controlled trials with serious flaws. Any estimate of effect is uncertain.

Evidence graded less than “A” is acceptable to support clinical recommendations in a guideline. It is also assumed that for many important clinical recommendations, it would be unlikely that level A evidence be obtained because appropriate studies may never be performed.

¹Guyatt G et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Physicians Task Force. *Chest* 129:174-181, 2006

Joslin Diabetes Center & Joslin Clinic
Clinical Guideline for Pharmacological Management of Type 2 Diabetes
 1/09/2009 (updated 11/2010)

The objective of the *Joslin Diabetes Center & Joslin Clinic Clinical Guideline for Pharmacological Management of Type 2 Diabetes* is to support clinical practice and influence clinical behavior to improve outcomes and assure quality of care according to accepted standards. The Guideline was established after careful review of current evidence, literature and clinical practice. This Guideline will be reviewed periodically and modified to reflect changes in clinical practice and available pharmacological information.

This Clinical Guideline is not intended to serve as a mandatory standard, but rather to provide a set of recommendations for patient care management. These recommendations are not a substitute for sound and reasonable clinical judgment or decision-making and do not exclude other options. Clinical care must be individualized to the specific needs of each patient and interventions must be tailored accordingly. The Guideline has been created to address initial presentations and treatment strategies in the adult non-pregnant patient population. The Guideline is not a substitution for full prescribing information. Refer to Joslin's *Clinical Guideline for Adults with Diabetes* for additional, more comprehensive information on diabetes care and management.

Diabetes Mellitus – Diagnostic Criteria (Non-Pregnant Adults)

- Casual plasma glucose ≥ 200 mg/dl and symptoms of diabetes (polyuria, polydipsia, ketoacidosis, or unexplained weight loss) **OR**
 - Fasting plasma glucose (FPG)* ≥ 126 mg/dl **OR**
 - Results of a 2-hour 75-g Oral Glucose Tolerance Test (OGTT)* ≥ 200 mg/dl
- * *These tests should be confirmed by a repeat test, on a different day, unless unequivocally high*



Goals of Glycemic Control for People with Diabetes¹

Biochemical Index	Normal	Goal ²
Fasting Plasma Glucose or Preprandial Glucose (mg/dl)	< 100	70 – 130
Postprandial 2 hours (mg/dl)	< 140	< 180
Bedtime Glucose (mg/dl)	< 120	90 – 150
A1C (%) - sustained	< 6%	< 7% ³

INITIAL TREATMENT STRATEGY


Medical nutrition therapy (MNT), physical activity, blood glucose monitoring and patient education are the cornerstones of diabetes management for all patients. Pharmacological management should be used in combination with MNT and physical activity. Current weight status and lifestyle should be considered when choosing initial pharmacological therapy.

Initial Presentation (Based on presentation of the items listed within each box)



Continued on next page

CONSIDERATIONS FOR SELECTING INITIAL NON-INSULIN ANTIHYPERGLYCEMIC THERAPY⁶




ANTIHYPERGLYCEMIC THERAPY . continued

Suggested well-studied combinations based on results of clinical studies. These do not preclude other combinations:

- Insulin secretagogue and metformin**
- Sulfonylurea and α -glucosidase inhibitor
- Thiazolidinediones and sulfonylurea**.⁹
- Thiazolidinediones and metformin**.⁹
- Thiazolidinediones and repaglinide⁹
- Thiazolidinediones and exenatide⁹
- Sulfonylurea and exenatide
- Metformin and exenatide
- Dipeptidyl Peptidase IV Inhibitors and sulfonylurea
- Dipeptidyl Peptidase IV Inhibitors and metformin**
- Dipeptidyl Peptidase IV Inhibitors and pioglitazone
- Colesevelam and sulfonylurea
- Colesevelam and metformin

** Also available in fixed combinations



Continued on next page

ANTIHYPERGLYCEMIC THERAPY, continued

A1C > 7.0% *OR*
Fasting Plasma Glucose > 130 mg/dl *OR*
2 Hour Postprandial Plasma Glucose > 180 mg/dl

Add:

**Additional Oral
Antihyperglycemic
Medication
of Different Class**¹⁰

- or*
- Insulin**^{10,11,12}
- or*
- GLP-1
agonist**¹⁰
- Consider starting with.
 - Intermediate-acting insulin (NPH) once or twice daily as part of a conventional program
 - Long-acting insulin (detemir or glargine) once or twice daily for basal therapy
 - Pre-supper insulin mixture (75/25 lispro, 50/50 lispro, 50/50 aspart, 70/30 aspart, 70/30 human insulin, or 50/50 human insulin)
 - Suggested starting dose for injectable insulin: 0.1-0.2 units/kg ideal body weight
 - Titrate/adjust insulin dosage to achieve glucose goals


↓

If target glucose not met after 2-4 months, consider:

- Changing to multidose insulin therapy using combination of rapid, short, intermediate, or long-acting insulin
 - Adding pre-meal rapid or short-acting insulin (e.g. aspart, glulisine, lispro or regular) pre-meals, to bedtime intermediate or long-acting insulin
 - Adding bedtime basal insulin and adjusting the rapid or short-acting insulin as needed if taking pre-meal insulin and postprandial glucose targets are met, but fasting glucose is elevated
 - Adding oral antihyperglycemic medication to reduce insulin resistance or improve glycemic control if already on insulin (metformin, TZDs¹³, sulfonylureas, α -glucosidase inhibitors, and colesevelam are approved for use in combination with insulin)
- ↓
- If post-prandial excursions predominate, refer to endocrinologist for intensification of therapy or for consideration of pramlintide use

Oral Antihyperglycemic Medications Available in the USA

Biguanides	TZDs (Thiazolidinedi- ones)	α - Glucosidase Inhibitors	Insulin Secretagogues	Dipeptidyl Peptidase IV Inhibitors (DPP-4 Inhibitors)	Bile Acid Sequestrant	Fixed Combinations
<ul style="list-style-type: none"> liquid metformin* (<i>Riomet</i>) metformin <p>(<i>Glucophage</i>)</p> <ul style="list-style-type: none"> metformin extended release (<i>Glucophage XR</i>, <i>Fortamet</i>, <i>Glumetza</i>) <p>(metformin and metformin ER available as generic medication)</p> <p>* Liquid formulation for patients unable to swallow pills</p>	<ul style="list-style-type: none"> pioglitazone (<i>Actos</i>) rosiglitazone (<i>Avandia</i>)⁹ 	<ul style="list-style-type: none"> acarbose (<i>Precose</i>) miglitol (<i>Glyset</i>) 	<p>Sulfonylureas</p> <ul style="list-style-type: none"> glimepiride (<i>Amaryl</i>) glipizide (<i>Glucotrol</i>) glipizide extended release (<i>Glucotrol XL</i>) glyburide (<i>Micronase</i>, <i>Diabeta</i>) micronized glyburide (<i>Glynase</i>) <p>(glimepiride, glipizide and glyburide are available as generic medications)</p> <p>Non-sulfonylurea Meglitinides</p> <ul style="list-style-type: none"> repaglinide (<i>Prandin</i>) <p>D-phenylalanine Derivatives</p> <ul style="list-style-type: none"> nateglinide (<i>Starlix</i>) 	<ul style="list-style-type: none"> sitagliptin (<i>Januvia</i>) 	<ul style="list-style-type: none"> colesevelam (<i>Welchol</i>) 	<ul style="list-style-type: none"> metformin and glipizide (<i>Metaglip</i>) metformin and glyburide (<i>Glucovance</i>) metformin and pioglitazone (<i>Actoplus met</i>) pioglitazone and glimepiride (<i>Duetact</i>) rosiglitazone and glimepiride (<i>Avandaryl</i>)⁹ rosiglitazone and metformin (<i>Avandamet</i>)⁹ sitagliptin and metformin (<i>Janumet</i>) repaglinide and metformin (<i>PrandiMet</i>)



Continued on next page

INJECTABLE DIABETES MEDICATIONS

INSULIN CHART¹⁴

Insulin Type	Product	Onset	Peak	Duration
Rapid-Acting				
Insulin aspart analog Insulin glulisine analog Insulin lispro analog	NovoLog Apidra Humalog	10 – 30 minutes	30 minutes – 3 hours	3 – 5 hours
Short-Acting				
Human Regular	Humulin R Novolin R	30-60 minutes	2 – 5 hours	up to 12 hours*
Intermediate-Acting				
Human NPH insulin	Humulin N Novolin N	90 minutes – 4 hours	4 – 12 hours	up to 24 hours**
Long-Acting				
Insulin detemir Insulin glargine	Levemir Lantus	45 minutes -4 hours	Minimal peak	up to 24 hours ***

Premixed Insulin Combinations

Insulin Type	
50% NPH; 50% Regular	Humulin 50/50
70% NPH; 30% Regular	Humulin 70/30
70% NPH; 30% Regular	Novolin 70/30
50% lispro protamine suspension, 50% lispro	Humalog Mix 50/50
50% aspart protamine suspension, 50% aspart	Novolog Mix 50/50
75% lispro protamine suspension, 25% lispro	Humalog Mix 75/25
70% aspart protamine suspension, 30% aspart	NovoLog Mix 70/30

*Usual clinical relevance can be less than 12 hours

** Usual clinical relevance can be less than 24 hours. Often requires twice daily dosing

*** Individual response may require twice daily dosing

INCRETIN MIMETICS AND NON-INSULIN SYNTHETIC ANALOGS

Product	Mechanism of Action	Type of Diabetes	# of Injections Per Day
Exenatide (Byetta)	Incretin mimetic that enhances glucose-dependent insulin secretion and several other antihyperglycemic actions of incretins.	2	2
Pramlintide (Symlin)	Synthetic analog of human amylin, a naturally occurring hormone made in the beta cells, which slows gastric emptying, suppresses glucagon secretion, and regulates food intake. A significant reduction in insulin dose may be required when insulin is used in conjunction with pramlintide.	1 and 2	1-4 (with meals)

Footnotes:

¹Laboratory methods measure plasma glucose. Most glucose monitors approved for home use calibrate whole blood glucose readings to plasma values. Plasma glucose values are 10-15% higher than whole blood glucose values. It is important for people with diabetes to know whether their meters and strips record whole blood or plasma results.

²Goals should be individualized based on the following, including: co-morbidity, age, duration of diabetes, hypoglycemic awareness.

³The true goal of care is to bring the A1C as close to normal as safely possible. A goal of < 7% is chosen as a practical level for most patients using medications that may cause hypoglycemia to avoid the risk of that complication. Achieving normal blood glucose is recommended if it can be done practically and safely.

⁴If diet history reveals markedly excessive carbohydrate intake, may consider initial trial of MNT and physical activity before initiating oral agent therapy even though glucose levels are above the thresholds listed.

⁵Some patients with type 2 diabetes initially stabilized on insulin may be considered for transition to non-insulin anti-hyperglycemic therapy as blood glucose control permits.

⁶A combination of two drugs of different classes may be used as initial pharmacotherapy when there is marked hyperglycemia or when MNT and physical activity alone have not resulted in an A1C of < 7.0%

⁷**FDA Requirements for LFT monitoring for thiazolidinediones (TZDs):**

If initial ALT is > 2.5 times normal, do not start this medication

Once TZD is started, monitor ALT periodically thereafter according to clinical judgement.

If ALT is > 2.5 times normal during treatment, check weekly. If rise persists or becomes 3 times > normal, **discontinue** TZD.

⁸Thiazolidinediones cause or exacerbate congestive heart failure in some patients. After initiation of TZDs and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain, dyspnea, and/or edema). If these signs and symptoms develop, the heart failure should be managed according to current standards of care. Furthermore, discontinuation or dose reduction of the TZD must be considered. TZDs are not recommended in patients with symptomatic heart failure or in patients with established NYHA Class III or IV heart failure.

⁹On September 23, 2010, the Food and Drug Administration (FDA) announced regulatory actions with respect to products containing rosiglitazone: Avandia® (rosiglitazone maleate) Tablets, Avandamet® (rosiglitazone maleate and metformin hydrochloride) Tablets and Avandaryl® (rosiglitazone maleate and glimepiride) Tablets. The FDA is requiring GlaxoSmithKline (GSK) to implement restrictions on the use of these products through a program to assure their safe use (i.e., Risk Evaluation and Mitigation Strategy or REMS) and additional safety labeling changes in response to the agency's review of data that suggest an elevated risk of cardiovascular events. GSK will be working with the FDA to implement the agency's requirement for a REMS and additional labeling changes. Additional information will be communicated when these measures are finalized. It will take several months to put the REMS program in place. Until the REMS program is in place, the FDA's decision allows current or potential users of rosiglitazone to continue or start using the medication after consultation with their health care provider about treatment options. Once the REMS program is in place a) Health care providers will need to be enrolled in the program in order to prescribe rosiglitazone containing products. b) Pharmacists will need to be enrolled in order to dispense rosiglitazone containing products. c) Patients will need to be enrolled in the program by their physician in order for them to begin or continue receiving rosiglitazone. d) Health care providers will have to attest to and document their patient's eligibility if they believe that their patient is a candidate for rosiglitazone. e) Patients will have to review statements describing the cardiovascular safety concerns with rosiglitazone and sign an acknowledgment of their understanding of the information. f) Current users of rosiglitazone will only be able to continue using the medication if they acknowledge and document that they understand the risks associated with the drug. g) Patients not already taking rosiglitazone can receive the medicine only if they are unable to achieve glycemic control on other medications and, in consultation with their health care provider, decide not to take pioglitazone for medical reasons.

¹⁰If therapeutic goals are not met, consider starting insulin. Stop exenatide and DPP-IV inhibitor when starting insulin.

¹¹May need to taper and discontinue some or all oral antihyperglycemic medications as insulin is initiated and adjusted, particularly if using short or rapid-acting and basal insulins.

¹²Pre- and postprandial blood glucose should be checked. Frequency of checking may vary between 1-4 times/day depending on individual patient and status of glycemic control.

¹³There is an increased risk for edema when insulin and a thiazolidinedione are used together. Rosiglitazone should not be used in combination with insulin.

¹⁴The onset, peak and duration of any insulin type depends on many factors. Patients may experience variations in timing and/or intensity of insulin activity due to dose, site of injection, temperature of the insulin, level of physical activity, in addition to other factors. Therefore, the time action profile (TAP) should be considered as only reasonable estimates of the action of an insulin.

Guideline Authors: Martin Abrahamson, MD, Richard Beaser, MD, Elizabeth Blair, ANP-BC, Om Ganda, MD, James Rosenzweig, MD, Howard Wolpert, MD, Alissa Segal Pharm D, CDE, Amy Campbell, MS, RD, CDE

Approved by Joslin Clinical Oversight Committee on 01/09/2009.

Glossary and Common Abbreviations

A1C: glycohemoglobin (hemoglobin A1C)
ALT: alanine aminotransferase
BMI: body mass index; normal = 18.5-24.9 kg/m²; overweight = 25.0-29.9 kg/m² (> 23 kg/m² in Asian populations); obese = \geq 30 kg/m² (23-27 kg/m² in Asian populations)
Casual plasma glucose: a random plasma glucose
CHF: congestive heart failure
CV: cardiovascular
DPP-4: Dipeptidyl Peptidase IV Inhibitors
FDA: Food and Drug Administration
FPG: fasting plasma glucose
G: gram
GLP-1: Glucagon-like peptide-1 is secreted by the intestinal L cell in response to food intake, impacting glucose regulation.
HS: bedtime
Incretin: hormone produced by the gastrointestinal tract in response to food intake and necessary for glucose homeostasis
Incretin mimetics: a class of agents used for managing type 2 diabetes that mimics the enhancement of glucose-dependent insulin secretion and other glucoregulatory actions of naturally occurring incretins
Kg: kilogram
LDL-C: low density lipoprotein, cholesterol
LFT: liver function tests
Mg: milligram
Mg/dl: milligram per deciliter
MNT (Medical Nutrition Therapy): Begins with assessment of overall nutrition status, followed by individualized prescription for treatment. Registered dietitian considers food intake, physical activity, course of any medical therapy, individual preferences and other factors.
Obesity: BMI \geq 30 kg/m²
Overweight: BMI = 25.0-29.9 kg/m²
PFTs: pulmonary function tests
Rx: treatment
TAP: time action profile
TZDs: thiazolidinediones

Joslin Clinical Oversight Committee

Om Ganda, MD - Chairperson	Melinda Maryniuk, MEd, RD, CDE
Richard Beaser, MD	Medha Munshi, MD
Elizabeth Blair, MS, ANP-BC, CDE	Kristi Silver, MD
Patty Bonsignore, MS, RN, CDE	Jo-Anne Rizzotto, MEd, RD, CDE
Amy Campbell, MS, RD, CDE	Susan Sjostrom, JD
Cathy Carver, ANP-BC, CDE	Kenneth Snow, MD
Jerry Cavallerano, OD, PhD	Robert Stanton, MD
David Feinbloom, MD	William Sullivan, MD
Richard Jackson, MD	Howard Wolpert, MD
Lori Laffel, MD, MPH	Martin J. Abrahamson, MD, <i>ex officio</i>

References for Joslin's Pharmacological Management of Type 2 Diabetes Guideline 1-9-09

Diagnosis

1. ADA Position Statement: Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2009; 32 (suppl 1): S62-S67
2. Nathan, DM, Kuenen,J, Borg,H Translating the A1c assay into estimated average glucose values. *Diabetes Care* 2008; 31: 1473-1478

Goals of Glycemic Control and Phrmacotherapy

1. American Diabetes Association. Standards of medical care in diabetes. *Diabetes Care* 2009; 32 (suppl 1): S13-S 61
3. Beaser, RS and Staff of Joslin Diabetes Center. *Joslin's Diabetes Deskbook for Primary Care Providers*. Second edition. Joslin Diabetes Center, Boston; 2007.
4. Diabetes Prevention and Control Program, Diabetes Guidelines Work Group. Massachusetts guidelines for adult diabetes care. Boston (MA): Massachusetts Department of Public Health; 2005 Jun.
5. Institute for Clinical Systems Improvement (ICSI). Management of type 2 diabetes mellitus. Bloomington (MN): Institute for Clinical Systems Improvement (ICS); 2005 Nov.

Oral Antihyperglycemic Therapy

1. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. *JAMA* 287:360-72, 2002.
2. Kimmel B and Inzucchi S. Oral agents for type 2 diabetes: an update. *Clinical Diabetes* 23:64-76, 2005.
3. Krentz AJ, Bailey CJ. Oral antidiabetic agents. *Drugs* 2005; 65(3):385-411.
4. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med* 131:281-303, 1999.
5. Kahn SE, Haffner SM, Heise MA, et. al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. *New England Journal of Medicine* 2006; 355: 2427-2443
6. Nathan, DM et al Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care* 2008; 31: DOI : 10.2337/dc 08-9025

Metformin

1. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. *Diabetes Metab* 26 Suppl 4:73-85, 2000.
2. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach. *Diabetes Care* 28:539-543, 2005.
3. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. *Diabetes Care*. 14: 342-343, 1991.
4. Garber AJ, Duncan TG, Goodman AM, Millis DJ, Rohlf JL Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-controlled, Dose-Response Trial. *Am J Med* 103:491-497, 1997.
5. Grant PJ. The effects of high and medium dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. *Diabetes Care* 19: 64-66, 1996.
6. Holstein A, Stumvoll M. Contraindications can damage your health--is metformin a case in point? *Diabetologia* 48:2454-9, 2005.
7. Inzucchi SE. Metformin and heart failure: innocent until proven guilty. *Diabetes Care* 28:2585-2587, 2005.
8. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. *Diabetes Care* 22:33-7, 1999.
9. McCormack J, Johns K, Tildesley H. Metformin's contraindications should be contraindicated. *CMAJ* 173:502-4, 2005.
10. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 352: 854-865, 1998.
11. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* 2006 Issue 4.
12. Salpeter S., Greyber E, Paternak G., Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. *Cochrane Database Sys Rev* 2006 Issue 4.
13. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. *Diabetes Care* 20:925-8, 1997.

Thiazolidinediones

1. Charbonnel B, Roden M, Urquhart J, Mariz S, Johns D, Mihm M, Wide M, Tan M. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with glipazide-based regimens. *Diabetologia* 48:553-60, 2005.
2. Davidson JA, Perez A, Zhang J, The Pioglitazone 343 Study Group. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. *Diabetes Obes Metab* 8:164-74, 2006.
3. Kulenovic I. Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes. *Med Arh* 60:179-81,

2006.

4. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. *Diabetes Care* 24:710-719, 2001.
5. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. *Circulation* 108:2941-8, 2003.
6. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Sr. et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA* 2006; 296(21):2572-2581.
7. Yki-Jarvinen, H. Thiazolidinediones. *New England Journal of Medicine* 2004; 351: 1106-1118
8. Nissen, SE, Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine* 2007; 356: 2457-2471
9. GlaxoSmithKline. GSK regulatory update on Avandia following EMA and FDA reviews: issued Thursday 23 September 2010. Available at: http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10103.htm. Accessed September 2010.
10. U.S. Food and Drug Administration. Postmarketing drug safety information for patients and providers. Q&A: Avandia (rosiglitazone). Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226976.htm>. Accessed September 2010.*
11. Woodcock J. United States Food and Drug Administration, Center for Drug Evaluation and Research. Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl). Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959>. Accessed October 2010.*

Insulin Secretagogues

1. Bailey CJ, Day C. Antidiabetic drugs. *Br J Cardiol* 10:128-36, 2003.
2. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. *Diabetes Care* 26:2075-80, 2003.
3. Dornhorst M. Insulotropic meglitinide analogues. *Lancet* 358:1709-15, 2001.
4. Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes. *Diabetes Res Clin Pract* 71:251-5, 2006.
5. Plosker, GI, Figgitt, DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. *Pharmacoeconomics* 22:389-411, 2004.
6. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. *Isr Med Assoc J.* 2005 7:75-7, 2005.

Alpha-Glucosidase Inhibitors

1. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. *Drugs* 46:1025-54, 1993.
2. Carlson RF. Miglitol and hepatotoxicity in type 2 diabetes mellitus. *Am Fam Physician* 62:315 -318, 2000.
3. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. *Eur Heart J* 25:10-6, 2004.
4. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. *Cochrane Database Syst Rev* 18; (2):CD003639, 2005.

Exenatide

1. DeFronzo RA et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 28:1092-1100, 2005.
2. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 27:2628-35, 2004.
3. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. *Diabetes Care* 26:2370-7, 2003.
4. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 143:559-69, 2005.
5. Iltz JL, Baker DE, Setter SM, Keith Campbell R. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. *Clin Ther* 28:652-65, 2006.
6. Kendall, DM et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 28:1083-1091, 2005.
7. Linnebjerg H, Kothare PA, Skrivaneck Z, de la Pena A, Atkins M, Ernest CS, Trautmann ME. Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. *Diabet Med* 23:240-5, 2006.
8. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. *Diabetes Technol Ther* 7:467-77, 2005.

DPP-IV Inhibitors

1. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. *J Clin Endocrinol Metab* 2008; 93(10):3703-3716.
2. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. *Diabetes Care* 2008; 31(8):1479-1484.

3. Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *Ann Pharmacother* 2006; 40(7-8):1336-1343.
4. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007; 30(8):1979-1987.

Bile Acid Sequestrants

1. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. *Arch Intern Med* 2008; 168(18):1975-1983.
2. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. *Diabetes Care* 2008; 31(8):1479-1484.
3. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. *Arch Intern Med* 2008; 168(14):1531-1540.

Combination Therapy with insulin

1. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus. *Ann Intern Med* 131:182-88, 1999.
2. Belcher G, Lambert C, Goh1 KL, Edwards G, Valbuena1 M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and glipazide. *Int J Clin Pract* 58:833-7, 2004.
3. Goudswaard AN, Furlong NJ, Valk GD, Stolk RP, Rutten GEHM. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. *Cochrane Database Sys Rev* 2006 Issue 4.
4. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. *Diabetes Obes Metab* 5:163-70, 2003.
5. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 27:1535-47, 2005.
6. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. *Diabetes Care* 29:554-9, 2006.
7. Yki-Jarvinen H et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia* 3:1-10, 2006.

Insulin

1. Baker A, Ahmed E, Mallias J, Home PD. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. *Diabetes Care* 21:1162-66, 1998.
2. Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. *Clin Ther* 27:S75-88, 2005.

3. Hirsch B, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. *Clin Diabetes* 23: 78-86, 2005.
4. Kennedy L, Herman WH, Strange P, Harris A for the GOAL A1C Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA_{1c} on glycemic control in patients with type 2 diabetes. *Diabetes Care* 29:1-8, 2006.
5. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, Vogelsang DA, Smith SA, Rizza RA, Isley WL. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. *Diabetes Care* 28:10-4, 2005.
6. Riddle MC. The Treat-to-Target Trial and related studies. *Endoc Pract.* 37:495-501, 2006.
7. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. *Diabetologia* 48:1988-95, 2005.
8. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. *Cochrane Database Syst Rev.* 2006 Apr 19;(2):CD003287.
9. Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L. Appropriate insulin regimen for type 2 diabetes: a multicenter randomized crossover study. *Diabetes Care* 23:1612-18, 2000.
10. Valensi P, Cosson E. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects? *Diabetes Metab* 31:4S34-4S39, 2005.

Pramlintide

1. Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C. Addition of pramlintide to insulin therapy lowers HbA_{1c} in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. *Diabetes Obes Metab* 5:408-14, 2003.
2. Hollander PA et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. *Diabetes Care* 26:784-790, 2003.
3. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. *Diabetes Care* 26:3074-9, 2003.
4. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. *Diabetes Care* 25:724-30, 2002.